A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Brief description of study

The purpose of the study is to characterize the safety and efficacy profile of a combination of anti-cancer therapies in participants with previously treated metastatic colorectal cancers. The effectiveness (how well the drug works) will be studied by looking at the percentage of participants whose cancer shrinks and/or disappears after treatment (objective response rate), how long it takes until their disease gets worse (progression-free survival), and how long participants will live (overall survival).

Clinical Study Identifier: s21-00873
ClinicalTrials.gov Identifier: NCT03377361
Principal Investigator: Nina Beri.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.